Document Detail

Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
MedLine Citation:
PMID:  7636506     Owner:  NLM     Status:  MEDLINE    
The use of two new assays was evaluated for predicting the response to interferon (IFN) therapy in patients with chronic hepatitis C. The genotype of hepatitis C virus (HCV) was established by an enzyme-linked immunosorbent assay based on genotype-specific recombinant peptides of the NS4 region (genotyping ELISA). The concentration of HCV RNA was measured by a branched DNA assay (bDNA assay). Seventy-eight patients received the same regimen of IFN alpha 2a. Of the 74 patients assessed who completed the program, 38 (51.4%) were responders; i.e., their serum aminotransferase levels remained normal for 6 months or longer after stopping IFN, while 36 (48.6%) were nonresponders. The results of the HCV genotype determined by the genotyping ELISA and by the polymerase chain reaction (PCR) assay based on genotype-specific primers were similar. The serum concentrations of HCV RNA as measured by the bDNA assay and by the competitive PCR assay correlated closely and significantly (r = 0.82, P < 0.001). Multiple logistic regression analysis showed that the serum concentration of HCV RNA determined by the bDNA assay, the HCV genotype determined by the genotyping ELISA, and the histology activity index (HAI) of the liver were independently associated with IFN efficacy. By using these three variables in combination, a predictive rate of 82.4% was obtained. A lower level of HCV RNA, genotype 2 and a lower HAI score for liver histology were predictive of a favorable response to IFN. Thus, the genotyping ELSIA and the bDNA assay appear to be useful for clinical management of patients receiving IFN therapy.
T Suzuki; E Tanaka; A Matsumoto; A Urushihara; T Sodeyama
Related Documents :
16410926 - Prevalence of hepatitis c virus infection and hcv genotypes among hemophiliacs in the s...
12785176 - Geographical distribution of hepatitis c virus genotypes in india.
19208886 - Limited genetic diversity among genotypes of enterocytozoon bieneusi strains isolated f...
15090786 - Clinical and immunological impact of hiv envelope v3 sequence variation after starting ...
20833746 - Rnase l releases a small rna from hcv rna that refolds into a potent pamp.
17418986 - Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by p...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of medical virology     Volume:  46     ISSN:  0146-6615     ISO Abbreviation:  J. Med. Virol.     Publication Date:  1995 Jun 
Date Detail:
Created Date:  1995-09-14     Completed Date:  1995-09-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7705876     Medline TA:  J Med Virol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  162-8     Citation Subset:  IM    
Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
Chronic Disease
Enzyme-Linked Immunosorbent Assay
Follow-Up Studies
Hepacivirus / genetics*
Hepatitis C / blood,  therapy*,  virology
Interferon Alfa-2a / adverse effects,  therapeutic use*
Interferon Type I, Recombinant / adverse effects,  therapeutic use
Middle Aged
Polymerase Chain Reaction
RNA, Viral / blood*
Reagent Kits, Diagnostic
Treatment Outcome
Reg. No./Substance:
0/Interferon Type I, Recombinant; 0/RNA, Viral; 0/Reagent Kits, Diagnostic; 76543-88-9/Interferon Alfa-2a; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mutations of some critical amino acid residues in the hepatitis B virus surface antigen.
Next Document:  Sequential respiratory syncytial virus and cytomegalovirus pneumonia following bone marrow transplan...